PARP1 and neoplasm: A recently published paper by Chan et al. investigated the effectiveness of another radio-iodinated PARP-ligand, namely [123I]I-CC1, in three tumor cell lines (PSN1, U87MG, and MDA-MD-231) derived from pancreatic cancer, glioblastoma, and breast cancer, respectively [31].